Testimony, Comments, & Letters

ABAC letter on the importance of federal programs and funding for ending HIV in the United States

AIDS Budget and Appropriations Coalition cochairs the HIV+Hepatitis Policy Institute, The AIDS Institute, NASTAD, and AIDS United wrote to the House Appropriations and Senate Appropriations Committees: “While we still do not have a cure or a vaccine, we have the science and tools to eventually end HIV in the U.S. through science-based prevention & treatment progs. However, public health progs across the country must have the sufficient funding and proper policies in place.”

read more

Comments on Medicare national coverage determination for long-acting injectable PrEP

On behalf of the HIV+Hepatitis Policy Institute, an organization dedicated to promoting quality and affordable healthcare for people living with or at risk of HIV, hepatitis, and other serious and chronic health conditions, we thank you for this opportunity to comment on a National Coverage Determination (NCD) by the Centers for Medicare and Medicaid Services (CMS) on the use of provider-administered pre-exposure prophylaxis (PrEP). The first provider-administered medication for HIV pre-exposure prophylaxis (Apretude or cabotegravir as PrEP) was approved by the Food and Drug Administration in January 2022. In August 2022, we wrote to you on behalf of 64 organizations to request that CMS quickly and efficiently evaluate provider-administered PrEP for a National Coverage Determination, which is the only pathway to coverage under Medicare Part B. We commend CMS on moving forward with the NCD process and urge CMS to approve the NCD for provider-administered PrEP.

read more

Letter in support for Utah SB 184, Prescription Cost Amendments

We strongly support SB 184, Prescription Cost Amendments, which would require health insurers to accept and count payments made on behalf of patients towards deductibles and out-of-pocket maximums. We thank you for holding a hearing on this important issue and ask that you consider and pass the bill.

read more

Comments in support of adding HIV to Medicare medication therapy management

We offer our strong support of adding HIV/AIDS as one of the chronic conditions to be included in the Medicare Part D Medication Therapy Management (MTM) program. The MTM program is designed to assure, with respect to targeted beneficiaries, that covered Part D drugs are appropriately used to optimize therapeutic outcomes through improved medication use, and to reduce the risk of adverse events, including adverse drug interactions.

read more

50 patient groups comment in response to the request for information on essential health benefits [CMS-9898-NC]

We believe that the EHB regulations governing prescription drugs have generally been working well for patients; however, we propose some areas for improvement and are very concerned that there has been a lack of enforcement of the EHB regulations, an erosion of essential health benefits over the years, and some insurers and pharmacy benefit managers (PBMs) are devising ways to skirt the intent of the EHB law and regulations. 

read more

Pin It on Pinterest